Natural polymeric nanocarriers in malignant glioma drug delivery and targeting

Gao, Yuan; Wang, Rui; Zhao, Lina; Liu, Anchang

doi:10.1080/1061186x.2021.1904250

Cited by 5 publications

(3 citation statements)

References 130 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, NP-mediated drug delivery gaining increased interest as a potential and non-invasive system to cure cerebral diseases. 124 , 125 PDA NPs are specifically internalized by specific regions of the BBB and the BBTB under receptor-mediated cellular transcytosis. However, penetrating tumor tissues to target the release of sufficient drug concentrations is a challenge for nanomedicine.…”

Section: Pda-based Nps and The Bbb And The Bbtbmentioning

confidence: 99%

PDA-Based Drug Delivery Nanosystems: A Potential Approach for Glioma Treatment

Wu¹,

Wei²,

Yu³

et al. 2022

IJN

View full text Add to dashboard Cite

Glioma is characterized by high mortality and low postoperative survival. Despite the availability of various therapeutic approaches and molecular typing, the treatment failure rate and the recurrence rate of glioma remain high. Given the limitations of existing therapeutic tools, nanotechnology has emerged as an alternative treatment option. Nanoparticles, such as polydopamine (PDA)-based nanoparticles, are embodied with reliable biodegradability, efficient drug loading rate, relatively low toxicity, considerable biocompatibility, excellent adhesion properties, precisely targeted delivery, and strong photothermal conversion properties. Therefore, they can further enhance the therapeutic effects in patients with glioma. Moreover, polydopamine contains pyrocatechol, amino and carboxyl groups, active double bonds, catechol, and other reactive groups that can react with biofunctional molecules containing amino, aldehyde, or sulfhydryl groups (main including, self-polymerization, non-covalent self-assembly, π-π stacking, electrostatic attraction interaction, chelation, coating and covalent co-assembly), which form a reversible dynamic covalent Schiff base bond that is extremely sensitive to pH values. Meanwhile, PDA has excellent adhesion capability that can be further functionally modified. Consequently, the aim of this review is to summarize the application of PDA-based NPs in glioma and to acquire insight into the therapeutic effect of the drug-loaded PDA-based nanocarriers (PDA NPs). A wealthy understanding and argument of these sides is anticipated to afford a better approach to develop more reasonable and valid PDA-based cancer nano-dru g delivery systems. Finally, we discuss the expectation for the prospective application of PDA in this sphere and some individual viewpoints.

show abstract

Section: Pda-based Nps and The Bbb And The Bbtbmentioning

confidence: 99%

PDA-Based Drug Delivery Nanosystems: A Potential Approach for Glioma Treatment

Wu¹,

Wei²,

Yu³

et al. 2022

IJN

View full text Add to dashboard Cite

show abstract

“…Gliomas are the most common cancer of the central nervous system (1), accounting for approximately 80% of all malignant tumors arising in the brain (2). Malignant gliomas has a high incidence and aggressiveness, and present numerous challenges for treatment (3). Based on the World Health Organization (WHO) classification in 2016, there are four grades of gliomas (I to IV) and patients with grade-IV gliomas have an average survival time of only 15 months (4,5).…”

Section: Introductionmentioning

confidence: 99%

The development of a redox-sensitive curcumin conjugated chitosan oligosaccharide nanocarrier for the efficient delivery of docetaxel to glioma cells

Liu¹,

Gao

Zhao³

et al. 2022

Ann Transl Med

Self Cite

View full text Add to dashboard Cite

Background: A redox-sensitive nanoscale delivery system was developed, based on the hydrophilic chitosan oligosaccharide-ss-hydrophobic curcumin conjugate (CSO-ss-CUR) loaded with docetaxel (DTX), for the targeting and synergistic treatment of gliomas.Methods: Redox-sensitive nanoparticles were loaded with DTX (DTX/CSO-ss-CUR) using the improved ultrasonic-dialysis approach. The morphology and particle size of the loaded nanoparticles were examined by transmission electron microscopy (TEM) and dynamic light scattering (DLS), respectively. The cytotoxicity and cellular uptake of the nanoparticles were assessed in vitro using the C6 glial cell line. The in vivo antitumor efficacy and in vivo biodistribution studies were evaluated using the C6 tumor-bearing Balb/c female mouse model. Results:The DTX/CSO-ss-CUR nanoparticles were generally spherical in shape and exhibited desirable particle size (under 250 nm) with high drug loading efficiency (DL) (8.96%±0.56%) and encapsulation efficiency (EE) (35.23%±3.26%). In vitro, the drug was released from the nanoparticles in a redox-sensitive manner. The DTX/CSO-ss-CUR nanoparticles exhibited superior hemocompatibility in the hemolytic test and in vitro cytotoxicity and live/dead cell staining experiments revealed a higher cytotoxicity to glioma cells compared to the free drug. Furthermore, in vitro uptake experiments using C6 glioma cells demonstrated that the CSO-ss-CUR nanoparticles had good cell penetration ability. The in vivo antitumor efficacy and in vivo biodistribution studies suggested that the CSO-ss-CUR nanoparticles could effectively inhibit C6 tumor growth. More importantly, after intravenous injection, more CSO-ss-CUR nanoparticles were concentrated in the brain of the mice than free 1,1-dioctadecyl-3,3,3,3-tetramethylindotricarbocyanine iodide (DiR) group.Conclusions: A unique drug delivery system formed by the self-assembly of CSO-ss-CUR was developed and shown to effectively cross the blood-brain barrier (BBB), enriching the abundance of the drug in the brain tissues. This may represent a potential therapeutic strategy for the treatment of gliomas.

show abstract

“…Glioma is a common malignant tumor [ 1 ]. Unfortunately, due to the presence of the blood–brain barrier (BBB) and the blood–brain tumor barrier (BBTB), most therapeutic drugs are not able to cross these physiological and metabolic barriers into the brain [ 2 , 3 , 4 , 5 ]. Methods that can make drugs enter the brain parenchyma through the BBB in order to reduce the systemic toxicity of drugs and play a therapeutic role need to be further researched [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

Cancer Cell Membrane-Coated Nanosuspensions for Enhanced Chemotherapeutic Treatment of Glioma

Fan

Hao²,

Cui³

et al. 2021

Molecules

View full text Add to dashboard Cite

Effective intracerebral delivery is key for glioma treatment. However, the drug delivery system within the brain is largely limited by its own adverse physical and chemical properties, low targeting efficiency, the blood–brain barrier and the blood–brain tumor barrier. Herein, we developed a simple, safe and efficient biomimetic nanosuspension. The C6 cell membrane (CCM) was utilized to camouflaged the 10-hydroxycamptothecin nanosuspension (HCPT-NS) in order to obtain HCPT-NS/CCM. Through the use of immune escape and homotypic binding of the cancer cell membrane, HCPT-NS/CCM was able to penetrate the blood–brain barrier and target tumors. The HCPT-NS is only comprised of drugs, as well as a small amount of stabilizers that are characterized by a simple preparation method and high drug loading. Similarly, the HCPT-NS/CCM is able to achieve targeted treatment of glioma without any ligand modification, which leads it to be stable and efficient. Cellular uptake and in vivo imaging experiments demonstrated that HCPT-NS/CCM is able to effectively cross the blood–brain barrier and was concentrated at the glioma site due to the natural homing pathway. Our results reveal that the glioma cancer cell membrane is able to promote drug transport into the brain and enter the tumor via a homologous targeting mechanism.

show abstract

Natural polymeric nanocarriers in malignant glioma drug delivery and targeting

Cited by 5 publications

References 130 publications

PDA-Based Drug Delivery Nanosystems: A Potential Approach for Glioma Treatment

PDA-Based Drug Delivery Nanosystems: A Potential Approach for Glioma Treatment

The development of a redox-sensitive curcumin conjugated chitosan oligosaccharide nanocarrier for the efficient delivery of docetaxel to glioma cells

Cancer Cell Membrane-Coated Nanosuspensions for Enhanced Chemotherapeutic Treatment of Glioma

Contact Info

Product

Resources

About